Antares Pharma Inc (ATRS) Expected to Announce Quarterly Sales of $18.10 Million

Brokerages expect that Antares Pharma Inc (NASDAQ:ATRS) will post sales of $18.10 million for the current quarter, according to Zacks. Five analysts have made estimates for Antares Pharma’s earnings, with estimates ranging from $16.40 million to $19.10 million. Antares Pharma posted sales of $14.04 million during the same quarter last year, which suggests a positive year over year growth rate of 28.9%. The business is expected to issue its next quarterly earnings results on Tuesday, March 12th.

On average, analysts expect that Antares Pharma will report full-year sales of $62.82 million for the current year, with estimates ranging from $61.10 million to $63.80 million. For the next financial year, analysts forecast that the business will post sales of $113.24 million, with estimates ranging from $98.50 million to $146.94 million. Zacks Investment Research’s sales averages are an average based on a survey of sell-side research firms that follow Antares Pharma.

Antares Pharma (NASDAQ:ATRS) last released its quarterly earnings data on Tuesday, November 6th. The specialty pharmaceutical company reported ($0.01) EPS for the quarter, topping analysts’ consensus estimates of ($0.02) by $0.01. The firm had revenue of $17.87 million for the quarter, compared to the consensus estimate of $15.13 million. Antares Pharma had a negative net margin of 27.84% and a negative return on equity of 59.08%.

ATRS has been the subject of a number of research reports. HC Wainwright restated a “buy” rating and set a $4.50 target price on shares of Antares Pharma in a research report on Wednesday, November 7th. Jefferies Financial Group lifted their target price on shares of Antares Pharma to $8.00 and gave the stock a “buy” rating in a research report on Tuesday, November 6th. Piper Jaffray Companies restated a “buy” rating and set a $4.00 target price on shares of Antares Pharma in a research report on Friday, August 17th. BidaskClub upgraded shares of Antares Pharma from a “hold” rating to a “buy” rating in a research report on Tuesday, August 14th. Finally, Raymond James lifted their target price on shares of Antares Pharma from $3.85 to $5.25 and gave the stock a “strong-buy” rating in a research report on Tuesday, October 2nd. One research analyst has rated the stock with a hold rating, four have issued a buy rating and one has assigned a strong buy rating to the stock. The stock has a consensus rating of “Buy” and an average target price of $5.44.

Shares of ATRS opened at $3.18 on Friday. The company has a quick ratio of 1.83, a current ratio of 2.29 and a debt-to-equity ratio of 1.03. The stock has a market cap of $537.22 million, a price-to-earnings ratio of -28.91 and a beta of 0.61. Antares Pharma has a 12-month low of $1.75 and a 12-month high of $3.93.

In other Antares Pharma news, Director Jacques Gonella sold 400,000 shares of Antares Pharma stock in a transaction dated Tuesday, October 2nd. The shares were sold at an average price of $3.79, for a total transaction of $1,516,000.00. Following the completion of the transaction, the director now owns 9,585,848 shares in the company, valued at $36,330,363.92. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Insiders own 12.20% of the company’s stock.

Large investors have recently bought and sold shares of the company. Russell Investments Group Ltd. lifted its stake in shares of Antares Pharma by 27.5% in the 2nd quarter. Russell Investments Group Ltd. now owns 1,135,517 shares of the specialty pharmaceutical company’s stock valued at $2,930,000 after acquiring an additional 245,032 shares during the last quarter. Schwab Charles Investment Management Inc. raised its position in Antares Pharma by 4.6% during the 2nd quarter. Schwab Charles Investment Management Inc. now owns 744,188 shares of the specialty pharmaceutical company’s stock valued at $1,921,000 after purchasing an additional 32,626 shares during the last quarter. BlackRock Inc. raised its position in Antares Pharma by 7.3% during the 2nd quarter. BlackRock Inc. now owns 9,805,325 shares of the specialty pharmaceutical company’s stock valued at $25,298,000 after purchasing an additional 664,681 shares during the last quarter. FMR LLC raised its position in Antares Pharma by 38.8% during the 2nd quarter. FMR LLC now owns 3,640,800 shares of the specialty pharmaceutical company’s stock valued at $9,393,000 after purchasing an additional 1,018,300 shares during the last quarter. Finally, JW Asset Management LLC raised its position in Antares Pharma by 2.8% during the 2nd quarter. JW Asset Management LLC now owns 1,820,524 shares of the specialty pharmaceutical company’s stock valued at $4,697,000 after purchasing an additional 50,000 shares during the last quarter. 37.27% of the stock is owned by institutional investors and hedge funds.

Antares Pharma Company Profile

Antares Pharma, Inc, a specialty pharmaceutical company, focuses on developing and commercializing self-administered parenteral pharmaceutical products and technologies worldwide. The company's injection products include OTREXUP that comprises of pre-filled methotrexate syringe and VIBEX self-injection system to enable rheumatoid arthritis (RA) and psoriasis patients to self-inject methotrexate at home; and Sumatriptan Injection USP for the acute treatment of migraine and cluster headache in adults.

See Also: Do stock splits help investors?

Get a free copy of the Zacks research report on Antares Pharma (ATRS)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Antares Pharma (NASDAQ:ATRS)

Receive News & Ratings for Antares Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Antares Pharma and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply